Sinclair and York enter UK co-promotion deal

Sinclair Pharma has entered into a commercial collaboration with fellow UK drugmaker York Pharma whereby each company will co-promote selected  products to dermatologists and selected general practitioners in their  home market.

Sinclair will co-promote certain York products, including the anti-acne  agent Zindaclin (clindamycin phosphate), and the emollient QV, while  York's sales force will co-market Sinclair's Atopiclair for atopic  dermatitis.

Michael Flynn, chief executive of Sinclair, said: "this agreement  effectively doubles the number of specialist salespersons promoting the  two companies' dermatology products in the UK. For Sinclair, this is  particularly important for the promotion of our reimbursed product  Atopiclair for the treatment of atopic dermatitis. We are exploring  similar synergies with York in other European countries."